Leaps. Org, Jul 27, 2023: This news story discusses the May, 2023, FDA approval of fezolinetant (brand name Veozah™) to treat hot flashes caused by menopause. While the drug was shown to slightly reduce the frequency and severity of hot flashes per day, NCHR and other experts question if these changes are sufficient to justify any risks and the high cost. We also suggest possible alternative strategies to deal with hot flashes.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
The real costs of the new Alzheimer’s drug, Leqembi — and why taxpayers will foot much of the bill
KFF Health News/CBS News, Aug 1, 2023: CBS News says that the drug Leqembi for mild cognitive impairment and early Alzheimer’s is likely to cost taxpayers billions of dollars. We are among the policy experts who tell Medicare that all registry data need to be public to see if it is safe or effective. Will that happen?
Read More »Biden’s Crackdown on ‘Junk’ Plans: Minimal Impact on Payers
Health Payer Specialist, July 14, 2023: The White House proposes restricting “junk” health insurance policies to 3-4 months for emergencies, instead of 3 years. These health insurance policies are supposed to be for short-term emergency coverage, not to replace comprehensive health insurance. We explain that these inexpensive policies result in patients paying much more if they have any medical needs – or going without important medical care. Don’t be fooled by misleading ads for cancer coverage or other limited coverage.
Read More »Medicare’s Registry Plans For Leqembi Prompt New Calls For Transparency, Rigor
Pink Sheet, August 2, 2023: This news article extensively describes 2 letters sent to CMS about the Leqembi registries: one from policy experts and one from 20 members of the Patient, Consumer, & Public Health Coalition. The article explains what these experts are asking Medicare to require of private registries for patients with mild cognitive impairment caused by early Alzheimer’s.
Read More »Policy experts call on Medicare to ensure data from Alzheimer’s drug registries is shared publicly
STAT, July 27, 2023: Prestigious health policy experts and ethicists sent a letter to CMS to urge Medicare to require all Alzheimer’s drug registries to share their de-identified data publicly to allow statistical analyses by CMS and others. NCHR explains why that is important, but Alzheimer’s Association and Beth Israel Hospital don’t plan to comply.
Read More »